Tabrecta Evrópusambandið - íslenska - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Biopoin Evrópusambandið - íslenska - EMA (European Medicines Agency)

biopoin

teva gmbh - epóetínþeta - kidney failure, chronic; anemia; cancer - Önnur antianemic undirbúningur - meðferð við blóðleysi með einkennum í tengslum við langvarandi nýrnabilun hjá fullorðnum sjúklingum. meðferð einkennum blóðleysi í fullorðinn krabbamein sjúklinga með ekki-merg illkynja fá lyfjameðferð.

Eporatio Evrópusambandið - íslenska - EMA (European Medicines Agency)

eporatio

ratiopharm gmbh - epóetínþeta - kidney failure, chronic; anemia; cancer - Önnur antianemic undirbúningur - meðferð við blóðleysi með einkennum í tengslum við langvarandi nýrnabilun hjá fullorðnum sjúklingum. meðferð einkennum blóðleysi í fullorðinn krabbamein sjúklinga með ekki-merg illkynja fá lyfjameðferð.

Nevanac Evrópusambandið - íslenska - EMA (European Medicines Agency)

nevanac

novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - augnlækningar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Opatanol Evrópusambandið - íslenska - EMA (European Medicines Agency)

opatanol

novartis europharm limited - olópatadínhýdróklóríð - konjunktarbólga, ofnæmi - augnlækningar - meðhöndlun á augnsjúkdómum og einkennum á árstíðabundinni ofnæmishálsbólgu.

Tribovax vet. Stungulyf, dreifa Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tribovax vet. stungulyf, dreifa

intervet international b.v.* - clostridium perfringens type a, alpha toxoid; clostridium perfringens type-b beta toxoid; clostridium perfringens type-c beta toxoid; clostridium perfringens type-d epsilon toxoid; clostridium novyi toxoid; clostridium septicum, toxoid; clostridium tetani, toxoid; clostridium sordellii, toxoid; clostridium haemolyticum, toxoid - stungulyf, dreifa

Xevudy Evrópusambandið - íslenska - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Ronapreve Evrópusambandið - íslenska - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. sjá kafla 4. 4 og 5.

Veklury Evrópusambandið - íslenska - EMA (European Medicines Agency)

veklury

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.